Biotech Values

[DewDiligence]

Notes on Viread for HBV (from GILD 3Q08 CC):

Precise Viread sales in HBV are not known because GILD cannot distinguish between use for HIV and HBV; however, it is already clear that Viread for HBV has surpassed lamivudine and Baraclude in EU market share.

Viread was approved for HBV in the US only two months ago, so there is not yet much to say about the sales ramp. The prospects are strong because Viread has a preferred reimbursement tier compared to Baraclude in most US insurance formularies.

GILD is no longer promoting Hepsera, although it continues to be available in all markets.